Dr. Reddys Laboratories (RDY)
(Delayed Data from NYSE)
$71.49 USD
-0.66 (-0.91%)
Updated Apr 23, 2024 04:00 PM ET
After-Market: $71.52 +0.03 (0.04%) 5:00 PM ET
4-Sell of 5 4
C Value C Growth D Momentum C VGM
Company Summary
India-based Dr. Reddy’s Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy’s operates through three segments: • Global Generics – This segment consists of unbranded prescription drugs along with over-the-counter (OTC) drugs. It includes the operations of the company’s biologics business. The segment accounted for about 87% of the company’s total revenues generated in the fiscal year 2023.
• ...
Company Summary
India-based Dr. Reddy’s Laboratories Ltd. is an integrated global pharmaceutical company engaged in providing affordable and innovative medicines since 1984. The company markets its products in countries like the U.S., UK, Germany, India, Russia, Venezuela, Romania and South Africa. Dr. Reddy’s operates through three segments: • Global Generics – This segment consists of unbranded prescription drugs along with over-the-counter (OTC) drugs. It includes the operations of the company’s biologics business. The segment accounted for about 87% of the company’s total revenues generated in the fiscal year 2023.
• Pharmaceutical Services & Active Ingredients (PSAI) – This segment is composed of active pharmaceutical ingredients (API) and custom pharmaceutical services. The segment accounted for about 12% of the company’s total revenues generated in the fiscal year 2023.
• Others – This segment involves the new chemical entities, the differentiated formulations business and a dermatology specialty business. The segment accounted for about 1% of the company’s total revenues generated in the fiscal year 2023.
Dr. Reddy’s reported fiscal 2023 (ending Mar 31, 2023) revenues of $2.99 billion. Global Generics contributed 87%, PSAI contributed 12%, and Proprietary Products and Others contributed 1% to total revenues in fiscal 2023.
The company has strategic partnerships with several pharma companies to market selected products across emerging markets outside India. In March 2023, Dr. Reddy’s signed a deal to divest certain non-core brands of the company in the dermatology segments to Eris Lifesciences Limited in India as part of a strategic decision to focus on strengthening its core business.
Dr. Reddy’s enjoys a strong position in the generics market. As of Dec 31, cumulatively, 79 generic filings were pending approval from the FDA (75 abbreviated new drug applications and four new drug applications). Of these 79 pending filings, 41 are Para IVs and 21 have first-to-file status. During FY23, Dr. Reddy’s completed 195 global generic filings, including 12 ANDAs filed in the United States and 130 drug master files filed globally, including 12 drug master files in the United States, and are on track to accelerate on this in FY24.
General Information
Dr Reddy's Laboratories Ltd
8-2-337 ROAD NO.3 BANJARA HILLS
HYDERABAD, K7 500-034
Phone: 91-40-4900-2900
Fax: 91-40-4900-2999
Email: spoddar@drreddys.com
| Industry | Medical - Generic Drugs |
| Sector | Medical |
| Fiscal Year End | March |
| Last Reported Quarter | 3/31/2024 |
| Exp Earnings Date | 5/8/2024 |
EPS Information
| Current Quarter EPS Consensus Estimate | 0.86 |
| Current Year EPS Consensus Estimate | 3.96 |
| Estimated Long-Term EPS Growth Rate | 9.70 |
| Exp Earnings Date | 5/8/2024 |
Price and Volume Information
| Zacks Rank |  |
| Yesterday's Close | 72.15 |
| 52 Week High | 77.72 |
| 52 Week Low | 53.12 |
| Beta | 0.58 |
| 20 Day Moving Average | 156,272.95 |
| Target Price Consensus | 73.33 |
| 4 Week | -1.72 |
| 12 Week | 3.01 |
| YTD | 3.69 |
| 4 Week | 2.36 |
| 12 Week | 1.31 |
| YTD | -1.29 |
| Shares Outstanding (millions) | 166.88 |
| Market Capitalization (millions) | 12,040.24 |
| Short Ratio | NA |
| Last Split Date | 9/7/2006 |
| Dividend Yield | 0.57% |
| Annual Dividend | $0.41 |
| Payout Ratio | 0.11 |
| Change in Payout Ratio | -0.01 |
| Last Dividend Payout / Amount | NA / $0.00 |
Fundamental Ratios
| P/E (F1) | 17.50 |
| Trailing 12 Months | 19.04 |
| PEG Ratio | 1.80 |
| vs. Previous Year | 8.79% |
| vs. Previous Quarter | -7.48% |
| vs. Previous Year | 5.99% |
| vs. Previous Quarter | 4.19% |
| Price/Book | 3.74 |
| Price/Cash Flow | 17.12 |
| Price / Sales | 3.66 |
| 3/31/24 | NA |
| 12/31/23 | 20.97 |
| 9/30/23 | 21.47 |
| 3/31/24 | NA |
| 12/31/23 | 15.19 |
| 9/30/23 | 15.52 |
| 3/31/24 | NA |
| 12/31/23 | 2.55 |
| 9/30/23 | 2.59 |
| 3/31/24 | NA |
| 12/31/23 | 1.90 |
| 9/30/23 | 1.91 |
| 3/31/24 | NA |
| 12/31/23 | 19.26 |
| 9/30/23 | 19.09 |
| 3/31/24 | NA |
| 12/31/23 | 19.26 |
| 9/30/23 | 19.09 |
| 3/31/24 | NA |
| 12/31/23 | 25.04 |
| 9/30/23 | 24.81 |
| 3/31/24 | NA |
| 12/31/23 | 19.30 |
| 9/30/23 | 18.26 |
| 3/31/24 | NA |
| 12/31/23 | 2.04 |
| 9/30/23 | 2.11 |
| 3/31/24 | NA |
| 12/31/23 | 0.02 |
| 9/30/23 | 0.02 |
| 3/31/24 | NA |
| 12/31/23 | 2.25 |
| 9/30/23 | 2.34 |